Sign in

    Kaitlin Cronin

    Director and Equity Research Analyst at Canaccord Genuity Group Inc.

    Kaitlin Cronin is a Director and Equity Research Analyst at Canaccord Genuity LLC, specializing in medical devices and healthcare sector coverage with a particular focus on companies such as Establishment Labs, Smith & Nephew, Enovis, Alphatec, Vericel, and InMode. She is recognized for issuing timely and data-driven Buy and Hold ratings, with published research notes and price targets, although specific performance metrics and rankings are not publicly disclosed. Cronin began her career after graduating from the Wharton School, worked as an Analyst at abrdn, Inc. from 2017 to 2021, and has been at Canaccord Genuity since August 2021, progressing to her current Director role. Her credentials include a strong academic background in finance and active roles in institutional investment research, with a focus on both qualitative and quantitative analysis within the healthcare sector.

    Kaitlin Cronin's questions to STRYKER (SYK) leadership

    Kaitlin Cronin's questions to STRYKER (SYK) leadership • Q3 2024

    Question

    Kaitlin Cronin inquired about Stryker's approach to the margin profile of potential acquisitions, asking if there is a minimum threshold or if the evaluation is more fluid.

    Answer

    CFO Glenn Boehnlein explained that while the company targets accretive deals, the timeline to achieve accretion can vary based on the type of acquisition. CEO Kevin Lobo added that as a high-growth company, Stryker is not deterred by initial earnings dilution for a strategic asset, knowing it will become accretive over time.

    Ask Fintool Equity Research AI